Empagliflozin for T2D easy on kidneys
08 Oct 2020
byJairia Dela Cruz
Use of the sodium–glucose cotransporter 2 inhibitor empagliflozin in the treatment of type 2 diabetes (T2D) is effective even in patients with lower renal function and regardless of albuminuria status, with benefits including estimated glomerular filtration rate (eGFR) preservation, reduced body mass index, and lower risk of major adverse kidney events compared with other glucose-lowering drugs, as shown in a real-world study.
